This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Plenty of Risks Remain In St. Jude's Stock

NEW YORK ( TheStreet) -- Wall Street can be a funny place some times, if not entirely irrational. While some stocks can often languish in the absence of good news if not drop, there are those that can thrive regardless of constant streams of negativity news. It's as if they've become bullet-proof.

St. Jude Medical (STJ - Get Report) fits this description -- much to the dismay of many bears, waiting patiently for the stock to get cheap.

There's no denying that St. Jude has enjoyed years of strong performances in the medical devices industry. But over the past several quarters, the company's solid reputation has taken hits. There have been concerns related to the company's Riata and Durata Leads, which is used by patients to help prevent (among other things) heart failures.

These leads, which help carry the electrical impulses to the heart and provide information from the heart to the devices, were reported to have malfunctioned from premature insulation failure. The unfortunate situation, which has resulted in several product recalls, has not only brought about class-action claims, but it has recently garnered the attention of the Food and Drug Administration. As it stands, St. Jude is now operating under several written warning from the FDA.
[Read: <a target="blank" data-add-tracking="true" href=""><em>Three Dividend Stocks Your Portfolio Is Begging You to Buy</em></a>]

This is just the negative public-relations issue. On the operating side, there have also been concerns about the company's ability to compete against rivals including Johnson & Johnson (JNJ) and Medtronic (MDT), which are seen as more nimble. The issue has been with St. Jude's product pipeline, which I've never thought inspired any sort of real confidence about future growth.

With such concerns, you would think that investors would approach the stock with surgical gloves to avoid getting their hands dirty. But the Street has other ideas. Despite coming off three consecutive dismal quarters, not only has the stock risen 32% over the past three months, but shares of St. Jude have soared almost 50% in the trailing 12 months.

I'm not blaming St. Jude here. It's not the company's fault that investors have fallen in love with the stock. But it does seem that investors are betting on hope and praying that St. Jude comes of out this situation intact. But I believe that's a bit too much to ask, especially for a stock that's already posted such strong gains. For St. Jude investors, it seems foolish to keep pressing your luck.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
STJ $76.20 0.00%
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs